VX-407
Small molecule
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06345755 NCT06345755 · Autosomal Dominant Polycystic Kidney Disease Registry: NCT06345755 | 1 | Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Enrollment up to Day 10); Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Enrollment up to Day 23) 2025-01-27 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
NCT07161037 NCT07161037 · Autosomal Dominant Polycystic Kidney Disease Registry: NCT07161037 | 2 | htTKV on MRI Over Time (Baseline up to End of Study (Week 52)) 2027-07-22 | In progress: results expected 22 Jul 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Autosomal Dominant Polycystic Kidney Disease: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| VX-407: this drug | Phase 2 | Small molecule | Polycystin-1 (PKD1 variants) | not yet graded | No reviewed efficacy summary in this indication | |
| Tolvaptan (Jynarque) | Approved | Small molecule | Vasopressin V2 receptor | Partial signal | NCT02160145: Annualized change in eGFR (REPRISE trial): -2.34 mL/min/1.73m2/year tolvaptan vs -3.61 mL/min/1.73m2/year placebo; difference 1.27 mL/min/1.73m2/year (95% CI 0.86-1.68), 35% reduction in decline, P<0.001 NCT00428948: Total kidney volume growth over 36 months: tolvaptan 2.78% per year vs placebo 5.61% per year; difference -2.71 percentage points per year (95% CI -3.27 to -2.15), p<0.0001 (n=819 and 458 analysed) (CT.gov posted results). | |
| AZD1613 | Phase 1 | Monoclonal antibody | PAPP-A | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4771261 | Phase 1 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Farabursen | —(overall) | RNA / oligonucleotide | miR-17 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow VX-407 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.